ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 1437

Journal of Clinical & Experimental Pathology received 1437 citations as per Google Scholar report

Journal of Clinical & Experimental Pathology peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • Cosmos IF
  • Ulrich's Periodicals Directory
  • RefSeek
  • Directory of Research Journal Indexing (DRJI)
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
  • world cat
  • journal seek genamics
  • j-gate
  • esji (eurasian scientific journal index)
Share This Page

Meningioma 1 (MN1) expression: Refined risk stratification in acute myeloid leukemia with normal cytogenetics (CN-AML)

9th World Digital Pathology & Pathologists Congress

Lamiaa Ibrahim

Mansoura Medical School, Egypt

Posters & Accepted Abstracts: J Clin Exp Pathol

DOI: 10.4172/2161-0681.C1.029

Abstract
Background: Prognostic stratification of cytogenetic normal acute myeloid leukemia (CN-AML) is an area of active research. Aim: The aim of this study was to determine the prognostic importance of the meningioma 1 (MN1) gene expression levels in CN-AML. Methods: One hundred patients with CN-AML were diagnosed and MN1 expressions were analyzed using quantitative real-time polymerase chain reaction. Results: High expressions were detected in 48 (48%) patients (expression range: 2.35â��31.99, mean: 13.9�±8.49) in comparison with 52 (52%) patients with low expression (expression range: 0.02â��2.3, mean: 0.68�±0.77). The course of the disease in patients with high MN1 expression was unfavorable. Patients with high MN1 expression was associated with significant low complete remission rate (62.5 vs. 8.4%, high vs. low MN1, P=0.001) and high mortality rate (75% vs. 46.1, P=0.03). AML patients with high MN1 expression tended to be refractory (37.5 vs. 19.2%, P=0.00) and relapse risk (54.1 vs. 23%, P=0.02). Multivariable analysis confirmed high MN1 expression as an independent risk factor for disease-free survival and overall survival. Conclusion: MN1 over expression independently predicts bad clinical outcome in CN-AML patients.
Biography

Email: loomy16@yahoo.com

Top